Cargando…
BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study
Clear cell renal cell carcinoma (ccRCC) is an immunologically vulnerable tumor entity, and immune checkpoint inhibitors are now widely used to treat patients with advanced disease. Whether and to what extent immune responses in ccRCC are shaped by genetic alterations, however, is only beginning to e...
Autores principales: | Friedhoff, Jana, Schneider, Felix, Jurcic, Christina, Endris, Volker, Kirchner, Martina, Sun, Angela, Bolnavu, Iulia, Pohl, Laura, Teroerde, Miriam, Kippenberger, Maximilian, Schwab, Constantin, Kaczorowski, Adam, Zschäbitz, Stefanie, Jäger, Dirk, Hohenfellner, Markus, Stenzinger, Albrecht, Duensing, Anette, Duensing, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198938/ https://www.ncbi.nlm.nih.gov/pubmed/36562826 http://dx.doi.org/10.1007/s00262-022-03346-7 |
Ejemplares similares
-
Digital Spatial Profiling Identifies the Tumor Periphery as a Highly Active Biological Niche in Clear Cell Renal Cell Carcinoma
por: Schneider, Felix, et al.
Publicado: (2023) -
Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities
por: Pohl, Laura, et al.
Publicado: (2022) -
Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery
por: Li, Jielin, et al.
Publicado: (2021) -
The BRCA2 mutation status shapes the immune phenotype of prostate cancer
por: Jenzer, Maximilian, et al.
Publicado: (2019) -
Mutations in BRCA2 and taxane resistance in prostate cancer
por: Nientiedt, Cathleen, et al.
Publicado: (2017)